NCT00438880 - Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

October 31, 2010

Study Completion Date

November 30, 2014

Conditions

Adult Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

Agatolimod Sodium

Given IV

RADIATION

Indium In-111 Ibritumomab Tiuxetan

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative study

PROCEDURE

Radionuclide Imaging

Undergo imaging scans

BIOLOGICAL

Rituximab

Given IV

PROCEDURE

Single Photon Emission Computed Tomography

Undergo imaging scans

RADIATION

Yttrium Y-90 Ibritumomab Tiuxetan

Given IV

Trial Locations (2)

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55905

Mayo Clinic, Rochester